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Next-generation sequencing (NGS) technologies have revolutionized the field of genomics and provided unprecedented op-
portunities for high-throughput analysis at the levels of genomics, transcriptomics and epigenetics. However, the cost of NGS 
is still prohibitive for many laboratories. It is imperative to address the trade-off between the sequencing depth and cost. In this 
review, we will discuss the effects of sequencing depth on the detection of genes, quantification of gene expression and dis-
covering of gene structural variants. This will provide readers information on choosing appropriate sequencing depth that best 
meet the needs of their particular project. 
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The capillary electrophoresis-based Sanger sequencing method 
[1] of sequencing by capillary electrophoresis is considered 
as a ‘first-generation’ technology, which has been em-
ployed in many whole genome sequencing projects and is 
considered as the ‘gold standard’ in terms of both read 
length and sequencing accuracy. In the relatively short time 
frame since 2005, several next-generation sequencing 
(NGS) technologies (also known as massively parallel se-
quencing) have emerged, including Roche 454, Illumina 
Hiseq 2000, ABI SOLiD, as well as single molecule se-
quencing technology of Helicos Biosciences and Pacific 
Biosciences [2], which could make it possible for even sin-
gle research groups to generate large amounts of sequence 
data very rapidly and at a substantially lower cost than 
Sanger method on the ABI 3730xl platform. The signifi-
cant advances in NGS are revolutionizing the field of ge-
nomics and provided unprecedented opportunities for high-         
throughput analysis at the level of genomics, transcriptom-
ics and epigenetics. 
NGS technologies have increased high-throughput ca-
pacity and reduced the cost, which makes it possible to use 
these new platforms for de novo sequencing of entire ge-
nomes of many species. To date, whole-genome sequencing 
of many non model species from microbes, plants to ani-
mals are available [3–5], facilitated by NGS approaches. 
For those organisms with a previously published reference 
genome sequence, NGS can be applied to their whole-      
genome resequencing [6] for variant discovery, such as sin-
gle-nucleotide polymorphisms (SNPs), insertions/deletions 
(InDels), and structural rearrangements. Besides, methods 
like RRL [7] and RAD [8,9] also allow for discovery of 
mutations in any non model organisms that are lack of ge-
nomic information. Apart from whole genome sequencing, 
there is much more interest in applying NGS platforms, 
coupled with DNA target capture technology [10] for fo-
cused analysis of specific genomic regions, such as intervals 
identified through single nucleotide polymorphism (SNP)-     
based association or linkage studies, candidate genes or the 
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whole exome.  
In addition to DNA sequencing, the massively parallel 
sequencing can be applied to sequence RNA, known as 
RNA-Seq [11]. Microarrays [12] have been recognized as 
the predominant method for large-scale studies at gene ex-
pression levels in past years. In comparison, RNA-Seq is a 
more powerful tool for comprehensive characterization of 
whole transcriptome at both gene and exon levels and with 
an additional ability to identify rare transcripts, new genes, 
novel splicing junctions and gene fusions. And because 
RNA-Seq approach does not require the knowledge of the 
genome sequence as a prerequisite, non model organisms 
could obtain transcripts information on the sequence level. 
Furthermore, analysis of small RNAs and other noncoding 
RNAs with massively parallel sequencing are likely to elu-
cidate the roles of those molecules in gene regulation [13]. 
Epigenetics is to study heritable gene regulation that does 
not involve the DNA sequence. Modified NGS protocols 
also allow for an unbiased assessment of DNA/histone 
modifications and DNA-protein interactions. The genome-       
wide single-base resolution of DNA methylation mapping 
has been performed using bisulfate sequencing [14,15]. 
Chromatin modifying protein binding can be mapped using 
chromatin immunoprecipitation sequencing (ChIP-Seq) 
[16]. 
The cost of NGS is still prohibitive for many laboratories. 
NGS platforms allow adding sample specific barcode 
(sometimes called index) to the library molecules. Then it 
would be cost-effective if multiple samples are multiplexed 
and sequenced in a single lane with appropriate sequencing 
depth. Therefore, one of the most important concerns about 
a particular NGS experiment is the requirement of sequenc-
ing depth. Here, we will discuss the effects of sequencing 
depth on the detection of genes, quantification of gene ex-
pression and discovering of structural variants. This will 
provide readers information on choosing appropriate se-
quencing depth that best suit the needs of their particular 
research. 
1  Effect of sequencing depth on gene discovery 
RNA-Seq has become a popular method for extracting the 
transcriptome information. The more the target is sequenced, 
the more genes are identified. This will presumably result in 
a more accurate estimation of the expression level. As a 
consequence, the ability to find genes and detect differential 
expression is determined by sequencing depth. Low se-
quencing depth only allows the detection of highly ex-
pressed genes. Deeper sequencing is required for those 
transcripts that are expressed at lower levels. This leads to 
the question of how many reads should be sufficient to cov-
er the transcriptome of a given sample.  
To address this question, we randomly sampled 1–116 
million reads from the total reads of three human samples 
(Figure 1). The number of genes detected was increasing 
rapidly, and reached the turning point at 20 million reads, 
with about 45% of ENSEMBL genes were identified. The 
gene number increased much slowly when the read size was 
larger than 20 million. The saturation plots were almost 
identical across the data from sample A and B. In compari-
son, sample C needed more reads to reach the same per-
centage of gene detected. The main reason behind the dif-
ference was the different RNA preparation method. Sample 
A and B used poly-A mRNA for sequencing while sample 
C used the total RNA with rRNA depletion. Non-coding 
RNA in sample C therefore has a clear influence in the rela-
tive proportion of protein coding genes.  
Similarly, Huang et al. RNA-Seq analyses for 10 matched 
pairs of cancer and normal tissues from HBV-related  
hepatocellular carcinoma (HCC) patients [17]. They ran-
domly sampled 565 million reads from the total raw reads 
from sample A39P and A39C separately. About 15 million 
raw reads were sufficient to identify more than 50% 
ENSEMBL genes. This number almost equalled to all de-
tectable expressed genes in a given human tissue. Another 
research [18] divided their 879 million 50 bp read data from 
RNA-Seq of cultured human B-cells set into smaller sets 
and analyzed how the detection of a gene varies with in-
creasing sequencing depth. The total 879-million-read data 
was assumed to give a comprehensive catalog of transcribed 
genes. Then the number of genes detected was assessed in 
fractions of total reads (final data). The number of genes 
detected reached a plateau at 50 million reads, with about 
75% of genes detected. With 100 million reads, 81% of 
genes were detected. For each additional 100 million reads, 
3% more genes were able to be detected on average. Fur-
thermore, expression level of genes also affects the number 
of genes detected. With 100 million reads, 80% of highly 
expressed genes (top 25th percentile) compared to 32% of 
the low expression genes (bottom 25th percentile) were de-
tected. 
Additional genes were able to be detected with more 
reads. However, once the saturation curve excess the turn-
ing point, increment of reads results in only a small number 
of additional genes. To address the trade-off between the  
 
 
Figure 1  Number of genes detected at different sequencing depths. 
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depth of RNA-Seq and the coverage of the transcriptome in 
an organism, Tarazona et al. [19] used new detections rate 
(NDR), the number of newly detected genes in 1 million 
additional reads, as a function of the sequencing depth for 
each of the three published data. Although all three experi-
ments saturation is not entirely reached, each data set has a 
different sequencing depth; NDRs at the highest depth are 
substantially different. The NDR value dropped from 232 to 
70, and then to 19, with 22, 45 and 200 million reads re-
spectively. In addition, NDR values are broadly similar 
across data sets for a given number of reads, suggesting that 
these saturation curves could be indicative for other human 
data sets generated by Illumina platform. 
2  Effect of sequencing depth on quantify gene 
expression 
If only the number of genes was concerned, 15 or 50 million 
reads could be an answer according to the above discussion. 
However, for most studies, accurate estimating of expres-
sion level is more important. Toung’s data [18] gave us a 
good advice. The expression values assessed by total 879 
million reads were set to be the final levels, the sequencing 
depth necessary to achieve these final levels was analyzed 
then. At least 400 million reads are needed, when 50% of 
the genes are required to be within 10% of their final meas-
urements. This is a too large number for most researchers.  
If we perform a RNA-Seq experiment using pair-end se-
quencing (2×100 bp) approach with 4 G per sample (equals 
to 20 M reads in single-end sequencing like 1×50 bp). With 
this popular depth for most studies at present, only 1%–2% 
of genes will have values that are within 10% of their final 
value. Even with 100 million reads, 6% of genes are within 
this margin of error. Furthermore, although 100 million 
reads is sufficient for detection of the majority of genes 
(72%), the expression levels of these genes deviate from 
their final value by 41% on average. In other words, if we 
only consider those highly expressed genes (50% of the 
total number), and we require these genes to be within 20% 
of the final measurements, about 170 million reads are 
needed. Another two studies by Mortazavi et al. [20] and 
Xu et al. [21] also illuminated that deeper sequencing depth 
was required for more accurate estimation of low expression 
genes. 
3  Effect of sequencing depth on structural var-
iant discovery 
Sequencing depth directly affects the accuracy of expression 
level estimation, and also affects the structural variant dis-
covery. Alternative splicing is an essential mechanism for 
increasing transcriptome plasticity and proteome diversity 
in eukaryotes. About 95% of human genes have alternative 
splicing, evaluated by a high-throughput sequencing results 
[22]. As a consequence, the number of splice junctions de-
tected in an experiment close relate to sequencing depth just 
as the number of genes do. With 100 million reads, 90% of 
transcripts and 76% of splicing junctions were detected 
(Figure 1). For each additional 100 million reads, 1% more 
transcripts and 4% more junctions were able to be detected 
on average. Furthermore, sufficient sequence coverage is 
also necessary to estimate the expression of different spliced 
isoforms and determine their relative abundance. At defi-
cient sequencing depth, low expressed isoforms have large 
deviation from the final level. What is even worse that the 
relative abundance between isoforms could be misjudged in 
some situation [18].  
The relative high false positive rate of variants such as 
SNVs and InDels discovered by RNA-Seq is still a problem 
[23]. In comparison, whole exome capture sequencing is 
one of the most frequency applied technique in SNV dis-
covering and subsequently identification of disease-associated 
alleles. The average depth has increased about three times 
from this method been applied. We have reviewed 29 pub-
lications of whole exome sequencing (Table 1), and found 
the common depth of exome seqencing was about 30–40× 
two years ago and about 60–100× recently.  
The depth bias in different exon area is the major prob-
lem encountered in exome seqencing, as show in Figure 2, 
about 20% exon region are less than 20× when the average 
depth is about 50×. The lower the depth is, the higher FDR 
would exist in SNV and InDel detection. Allele bias is a 
neglected problem caused by different hybridization effi-
ciency for reference sequence and mutant sequence. The 
mutant fragment has less opportunity than the right se-
quence which is perfect match of the probe. It is difficult to 
calculate the reference-bias for the effect of GC content and 
hybridization Tm [53]. 
Allelic balance (AB) was calculated by determining the 
ratio of reference base calls over the total number of calls at 
every SNV (AB=0.53–0.55) [54]. We apply ABR (Allele 
Bias Rate), ABR=ref depth/alt depth, to study whether the 
bias of InDel is higher than SNV. We also calculate the 
change of SNV/InDel number and ABR along with depth 
increment using an exome data (186 M mapped reads) in 
order to estimate the proper depth sufficient (Figure 3). The 
result shows that the number of SNV in whole genome keep 
rising with the depth increment and much higher than SNV 
number in exon, which saturated at 10 G mapped data, 
which means that the low depth region outside exon result 
in a lot of false positive. The InDel number in exon or 
whole genome saturated at 10 G mapped data, which means 
that the accuracy of InDel in lower coveraged region is 
much higher than SNV.   
ABR of InDel is higher than SNV because InDel forms 
loop structure and reduces the stability of the double strands. 
ABR of SNV and InDel change slightly from 1.2 to 1.3  
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Table 1  Sequencing depth in publicationsa) 
Date Sequencing platform Capture platform Depth/Sample Reference 
Nov 2009 GA II Agilent 244 K microarrays 40× [24] 
May 2010 SOLiD Agilent 43× [25] 
Jan 2011 GA II+HiSeq 2000 Agilent 38 M 116× [26] 
Apr 2011 GA IIx 2×76 Agilent 16 G, ~180× [27] 
Jun 2011 GA II 2×78 Agilent Two lanes (*about 10 G, 100-130×) [28] 
Jul 2011 GAII Agilent 38 M 11.7–13.4 G [29] 
Aug 2011 GA II 2×75 Agilent 38 M 98× [30] 
Aug 2011 HiSeq 2000 2×50 Agilent 7.3 G (*about 70–900×) [31] 
Aug 2011 GA II 2×101 Agilent One lane (*about 6–7 G, 60–80×) [32] 
Dec 2011 GA II Agilent 50 M ~65× [33] 
Dec 2011 GA IIx 2×76 SeqCap EZ 1.4-5.7 G, 27–163× [34] 
May 2012 GA II+HiSeq 2000 Agilent ~80× [35] 
May 2012 GA II 1×75 Agilent’s Custom design 32× [36] 
May 2012 HiSeq Agilent 38 M 118× [37] 
Jun 2012 SOLiD 4 Agilent 50 M 1/4 run [38] 
Jun 2012 HiSeq 2000 2×100 Agilent 50 M 93% target >30× [39] 
Jul 2012 GA II+HiSeq 2000 Agilent 50 M 90× [40] 
Jul 2012 HiSeq 2000 2×101 Agilent 50 M 30–35 G [41] 
Jul 2012 SOLiD 4 Agilent 50 M 43× [42] 
Jul 2012 GA II 2×76 Nimblegen SeqCap EZ 86× [43] 
Jul 2012 HiSeq 2000 2×76 NA 103× [44] 
Jul 2012 GA IIx + HiSeq 2000 2×76 Nimblegen SeqCap EZ 65±14.8× [45] 
Aug 2012 HiSeq 2000 Agilent 38 M >100× (>11 G) [46] 
Aug 2012 GA II 1×75+SOLiD NimbleGen+Agilent 28×, 88× [47] 
Sept 2012 GA II 2×95 agilent 38 M 190× [48] 
Sept 2012 HiSeq 2000 2×75 Agilent 38 M+50 M 80×, 162× [49] 
Sept 2012 HiSeq 2000 Agilent 38 M 56× [50] 
Sept 2012 GA II 2×75 Agilent 38 M 6.9 G (*about 60–80×） [51] 
Oct 2012 HiSeq 2000 2×100 Agilent 63× [52] 




Figure 2  Coverage of 1× and 20× regions at different sequencing 
depths. 
when depth increasing, which means that the bias is com-
mon but slight. The increment of InDel ABR may be caused 
by new InDels detected with lagre ABR when depth in-
creasing. In summary, 10 G of mapped data (average se-
quencing depth about 100×) will be appropriate for exome 
seqencing, which matches the current trend.  
4  Conclusion 
In this study, we have discussed the effects of sequencing 
depth on detection of genes, quantification of gene expres-
sion and discovering of structural variants. The results indi-
cated that although RNA-Seq effectively enhances our view 
on the diversity of the transcriptome, the quantification of 
true expression at a low depth might not be so easy to 
achieve. In practice, 15–50 million reads allow to detect the 
majority of genes in human tissue. However, at least 170 
million reads are needed, when 50% of the genes were re-
quired to be within 20% of their final measurements. For 
the detection of splicing junctions, similar results were 
reached. For variants such as SNVs and InDels, exome se- 
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Figure 3  Number of varients (A) and ABR value (B) at different sequencing depths. 
quencing is a powerful approach, and 10 G of mapped data 
(about 100×) will be appropriate for most studies, which 
matches the current trend. 
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